Science

Despite the successes in immuno-oncology, less than 50% of individuals with cancer obtain a durable response. To fill this improvement potential, GlycoTherapeutics develops first-in-class anticancer drugs targeting sialic acid and fucose sugars. These sugars are overexpressed among many cancer types and are known to promote tumor progression by evasion of an immune response, increasing metastasis, increasing proliferation, and inducing resistance to therapies.